1. Szeto C.C., Sugano K., Wang J.G., Fujimoto K., Whittle S., Modi G.K., Chen C.H., Park J.B., Tam L.S., Vareesangthip K., Tsoi K.K.F., Chan F.K.L. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. 2020; 69(4):617–29.
2. Han M.H., Nam J.H., Noh E., Lee E.K. Gastrointestinal risk of non-steroidal anti-inflammatory drugs and gastroprotective agents used in the treatment of osteoarthritis in elderly patients: a nationwide retrospective cohort study. Int J Clin. Pharmacol Ther 2019; 57(11):531–51.
3. Laine L., White W.B., Rostom A., Hochberg M. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum. 2008; 38(3):165–187.
4. Sturov N.V. Safety of NSAIDs in long-term use. Difficult Patient. 2009; 10(7).
5. Zoryan A.V., Zoryan E.V., Daurova F.Y. To the choice of anti-inflammatory therapy in endodontics. Endodontics Today. 2016; 14(1):42-46.